CL2016000883A1 - Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma. - Google Patents

Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma.

Info

Publication number
CL2016000883A1
CL2016000883A1 CL2016000883A CL2016000883A CL2016000883A1 CL 2016000883 A1 CL2016000883 A1 CL 2016000883A1 CL 2016000883 A CL2016000883 A CL 2016000883A CL 2016000883 A CL2016000883 A CL 2016000883A CL 2016000883 A1 CL2016000883 A1 CL 2016000883A1
Authority
CL
Chile
Prior art keywords
psma
pharmaceutical composition
treatment
metal complex
inhibitors
Prior art date
Application number
CL2016000883A
Other languages
English (en)
Spanish (es)
Inventor
Mathias Eder
Klaus Kopka
Martin Schäfer
Ulrike Bauder-Wüst
Uwe Haberkorn
Michael Eisenhut
Walter Mier
Martina Benesova
Original Assignee
Deutsches Krebsforsch
Univ Heidelberg Ruprecht Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51903864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000883(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP20130004991 external-priority patent/EP2862857A1/en
Application filed by Deutsches Krebsforsch, Univ Heidelberg Ruprecht Karls filed Critical Deutsches Krebsforsch
Publication of CL2016000883A1 publication Critical patent/CL2016000883A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nuclear Medicine (AREA)
CL2016000883A 2013-10-18 2016-04-14 Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma. CL2016000883A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20130004991 EP2862857A1 (en) 2013-10-18 2013-10-18 Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP14175612 2014-07-03

Publications (1)

Publication Number Publication Date
CL2016000883A1 true CL2016000883A1 (es) 2016-10-21

Family

ID=51903864

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000883A CL2016000883A1 (es) 2013-10-18 2016-04-14 Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma.

Country Status (34)

Country Link
US (11) US20160228587A1 (enExample)
EP (6) EP3415489A1 (enExample)
JP (7) JP2016535013A (enExample)
KR (3) KR102282378B1 (enExample)
CN (2) CN109053616B (enExample)
AU (3) AU2014336638C1 (enExample)
CA (1) CA2924360C (enExample)
CL (1) CL2016000883A1 (enExample)
CY (1) CY2024023I2 (enExample)
DE (2) DE202014011600U1 (enExample)
DK (1) DK4095130T3 (enExample)
EA (1) EA037778B1 (enExample)
ES (1) ES2977715T3 (enExample)
FI (2) FI4095130T3 (enExample)
FR (1) FR24C1028I2 (enExample)
GE (8) GEP20237497B (enExample)
HR (1) HRP20240398T1 (enExample)
HU (2) HUE066137T2 (enExample)
IL (2) IL245113B (enExample)
LT (2) LT4095130T (enExample)
MX (3) MX2016005013A (enExample)
MY (2) MY188934A (enExample)
NL (1) NL301281I2 (enExample)
NZ (1) NZ718812A (enExample)
PE (2) PE20160678A1 (enExample)
PH (2) PH12019502571A1 (enExample)
PL (1) PL4095130T3 (enExample)
RS (1) RS65324B1 (enExample)
SA (1) SA516370842B1 (enExample)
SG (1) SG11201602249RA (enExample)
SI (1) SI4095130T1 (enExample)
TN (1) TN2016000137A1 (enExample)
WO (1) WO2015055318A1 (enExample)
ZA (2) ZA201603380B (enExample)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2547481T3 (es) 2006-11-08 2015-10-06 Molecular Insight Pharmaceuticals, Inc. Heterodímeros de ácido glutámico
EP3838298B1 (en) 2007-08-17 2025-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
HK1211493A1 (en) 2012-11-15 2016-05-27 恩多塞特公司 Conjugates for treating diseases caused by psma expressing cells
EP3415489A1 (en) * 2013-10-18 2018-12-19 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
SG10201803618RA (en) 2013-11-14 2018-06-28 Endocyte Inc Compounds for positron emission tomography
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3337520A1 (en) * 2015-08-20 2018-06-27 Universität zu Köln Pain tracking by pet-imaging (pain-trap)
EP3805250A1 (en) 2015-09-30 2021-04-14 Deutsches Krebsforschungszentrum Improved 18f - tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
DK3925952T3 (da) * 2016-03-22 2024-02-05 Univ Johns Hopkins Prostataspecifik membranantigen-målrettede højaffinitetsmidler til endoradioterapi af prostatacancer / Prostate-Specific Membrane Antigen Targeted High-Affinity Agents For Endoradiotherapy Of Prostate Cancer
WO2017223357A1 (en) 2016-06-23 2017-12-28 Cornell University Double targeted constructs to affect tumor kill
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
US10980901B2 (en) * 2016-12-15 2021-04-20 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of PMSA expressing cancers
NZ758176A (en) * 2017-04-05 2025-12-19 Univ Cornell Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
JP7373998B2 (ja) 2017-05-02 2023-11-06 コーネル・ユニバーシティー 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
EA201992595A1 (ru) 2017-05-05 2020-04-21 Фьюжн Фармасьютикалс Инк. Усиление фармакокинетики бифункциональных хелатов и их применения
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
MA49398A (fr) 2017-05-05 2020-04-22 Eric Steven Burak Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci
WO2018233798A1 (en) 2017-06-20 2018-12-27 ITM Isotopen Technologien München AG Novel psma-binding agents and uses thereof
AU2018274184B2 (en) * 2017-05-24 2024-06-13 ITM Isotope Technologies Munich SE Novel PSMA-binding agents and uses thereof
CN111032632B (zh) * 2017-05-30 2024-04-12 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
CA3065133A1 (en) 2017-06-09 2018-12-13 Gemoab Monoclonals Gmbh Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders
CN109510925A (zh) 2017-09-15 2019-03-22 南昌欧菲光电技术有限公司 摄像模组
CN109510921B (zh) 2017-09-15 2025-01-10 南昌欧菲光电技术有限公司 摄像模组
CN207184660U (zh) 2017-09-15 2018-04-03 南昌欧菲光电技术有限公司 摄像模组
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
US11452786B2 (en) 2017-11-13 2022-09-27 Deutsches Krebsforschungszentrum Double-labeled probe for molecular imaging and use thereof
AU2018373675B2 (en) * 2017-11-21 2022-06-16 Deutsches Krebsforschungszentrum A double-labeled probe for molecular imaging and use thereof
PT3723815T (pt) * 2017-12-11 2022-05-30 Univ Muenchen Tech Ligandos psma para imagiologia e endorradioterapia
IL275317B (en) * 2017-12-13 2022-09-01 Sciencons AS A complex containing a compound against psma attached to a radioactive nucleus of lead or thorium
US11813340B2 (en) 2018-02-06 2023-11-14 The Johns Hopkins University PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
MX380340B (es) * 2018-03-14 2025-03-11 Instituto Nac De Investigaciones Nucleares 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana.
HRP20230604T1 (hr) 2018-03-30 2023-09-29 Futurechem Co., Ltd. Radiofarmaceutik usmjeren na psma, namijenjen dijagnosticiranju i liječenju raka prostate
EP3781215A4 (en) * 2018-04-17 2021-12-29 Endocyte, Inc. Methods of treating cancer
EP3853213A4 (en) * 2018-09-21 2022-07-06 Endocyte, Inc. Shielding agents and their use
WO2020061458A1 (en) * 2018-09-21 2020-03-26 Endocyte, Inc. Methods of treating cancer
US20210393809A1 (en) * 2018-09-28 2021-12-23 Universität Heidelbert Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
DE102018126558A1 (de) 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
EP3897751A4 (en) 2018-12-18 2022-11-30 Provincial Health Services Authority 18F-LABELED DUAL MODE THERANOSTIC COMPOUNDS AND THEIR USES
CA3128401A1 (en) * 2019-01-30 2020-08-06 Technische Universitat Munchen Psma binding dual mode radiotracer and -therapeutics
EP3923997A1 (en) 2019-02-14 2021-12-22 Deutsches Krebsforschungszentrum Prostate specific membrane antigen (psma) ligands comprising an amylase cleavable linker
WO2020165420A1 (en) 2019-02-14 2020-08-20 Ruprecht-Karls-Universität Heidelberg Prostate specific membrane antigen (psma) ligands with improved tissue specificity
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
PL239934B1 (pl) 2019-04-12 2022-01-31 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty
CA3136979A1 (en) * 2019-04-17 2020-10-22 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer
MX2021013055A (es) * 2019-04-26 2021-12-10 Five Eleven Pharma Inc Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos.
CN120097930A (zh) * 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法
KR20220024595A (ko) 2019-06-21 2022-03-03 프로빈셜 헬스 서비시즈 오쏘리티 전립선-특이적 막 항원을 표적으로 하는 방사성표지 화합물
BR112021026812A2 (pt) * 2019-07-02 2022-02-22 Advanced Accelerator Applications Italy Srl Ligantes de antígeno de membrana específico da próstata (psma) e usos dos mesmos
US20230072421A1 (en) 2019-07-25 2023-03-09 Bayer As Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer
KR102269315B1 (ko) 2019-10-24 2021-06-24 서울대학교산학협력단 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물
DE102019135564B4 (de) 2019-12-20 2022-05-19 Johannes-Gutenberg-Universität Mainz Verbindung für Smart-Drug-Delivery und pharmazeutisches Kit für duale nuklearmedizinisch-cytotoxische Theranostik
US20230098279A1 (en) * 2020-02-18 2023-03-30 Endocyte, Inc. Method of treating psma-expressing cancers
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
WO2021202376A1 (en) 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
AU2021267477A1 (en) * 2020-05-06 2022-12-01 Cornell University Copper-containing theragnostic compounds and methods of use
EP3919082A1 (en) * 2020-06-04 2021-12-08 Rigshospitalet Psma targeting urea-based ligands for prostate cancer radiotherapy and imaging
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
TW202216205A (zh) 2020-07-13 2022-05-01 加拿大商波因特生物製藥股份有限公司 放射性藥劑及方法
CN112062695B (zh) * 2020-08-14 2021-04-06 北京大学第一医院 一种前列腺特异性膜抗原靶向抑制剂及应用和探针
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
CN112321673B (zh) * 2020-11-04 2022-09-20 北京市肿瘤防治研究所 一种前列腺特异性膜抗原靶向抑制剂及应用和探针
WO2022096103A1 (en) 2020-11-05 2022-05-12 ITM Isotopen Technologien München AG Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
JP2023550411A (ja) * 2020-11-19 2023-12-01 ノバルティス アーゲー 前立腺特異的膜抗原（ｐｓｍａ）リガンドの合成
WO2022111800A1 (en) 2020-11-25 2022-06-02 Itm Solucin Gmbh Stable formulations for radionuclide complexes
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
DE102021101216A1 (de) 2021-01-21 2022-07-21 Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen
CN112898270B (zh) * 2021-01-22 2023-03-21 周彤 一种诊疗一体的psma抑制剂、化合物及其制备方法与用途
CN116745323A (zh) 2021-01-22 2023-09-12 拜耳股份有限公司 Lrrc15抗体及其缀合物
CN112851637B (zh) * 2021-01-22 2022-11-18 北京瑞达福明科技有限公司 一种psma抑制剂、化合物及其制备方法与用途
CA3206250A1 (en) 2021-02-08 2022-08-11 Mark RIJPKEMA Psma-targeting ligands for multimodal applications
JP2024517657A (ja) 2021-04-23 2024-04-23 ウイスコンシン アラムナイ リサーチ ファウンデーシヨン 画像化および治療に最適な特性を備えた ｐｓｍａ 標的リガンド
JP2024519970A (ja) * 2021-05-21 2024-05-21 ノーススター メディカル テクノロジーズ リミテッド ライアビリティ カンパニー 三価放射性同位体生物標的放射性医薬品、調製方法及び使用
CN113372285B (zh) * 2021-05-28 2024-06-18 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用
DE102021114711B4 (de) 2021-06-08 2023-11-02 Medianezia GmbH Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer
US20240293586A1 (en) 2021-07-30 2024-09-05 Osaka University Radiolabeled compound and use thereof
CN117615795A (zh) * 2021-09-01 2024-02-27 天津恒瑞医药有限公司 前列腺特异性膜抗原的抑制剂及其医药用途
CN118852044A (zh) 2021-09-03 2024-10-29 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CN115806529A (zh) * 2021-09-15 2023-03-17 威智医药有限公司 Psma结合剂及其用途
CN114014843B (zh) * 2021-11-17 2022-09-20 北京大学第一医院 一种psma靶向核素/荧光双模态配体和分子探针与应用
EP4474379A1 (en) * 2022-01-30 2024-12-11 Bivision Pharmaceuticals, Inc Peptide urea derivative, pharmaceutical composition containing peptide urea derivative, and application of peptide urea derivative
WO2023208928A1 (en) 2022-04-26 2023-11-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Dosage of psma-ligands for fluorescence based detection of cancerous tissue
CN119255823A (zh) 2022-05-17 2025-01-03 德国癌症研究中心公共法律基金会 前列腺特异性膜抗原(psma)配体
WO2023222679A1 (en) 2022-05-17 2023-11-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Prostate specific membrane antigen (psma) ligands
KR20250011148A (ko) 2022-05-17 2025-01-21 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 전립선-특이적 막 항원(psma) 리간드
AU2023272273A1 (en) 2022-05-17 2024-10-31 Albert-Ludwigs-Universität Freiburg Prostate specific membrane antigen (psma) ligands with improved renal clearance
CN114874122A (zh) * 2022-05-31 2022-08-09 南京航空航天大学 一种新的小分子抑制剂及其制备方法和应用
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
CN119343151A (zh) 2022-06-10 2025-01-21 北京大学 一种三功能化合物及其用途
CN120282804A (zh) 2022-09-23 2025-07-08 核素迪姆股份公司 高纯度铜放射性药物组合物及其诊断和治疗用途
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
AU2024208501A1 (en) 2023-01-10 2025-07-24 Sun Pharma Advanced Research Company Limited Ligand-drug conjugates
US12539339B2 (en) * 2023-03-24 2026-02-03 Jubilant Draximage Inc. Radiopharmaceutical conjugate compound for diagnosis and/or therapeutic uses thereof
WO2025022285A2 (en) 2023-07-21 2025-01-30 Novartis Ag Psma-targeting radioligand treatment regimen
US20250213705A1 (en) 2023-08-23 2025-07-03 Bright Peak Therapeutics Ag Psma targeting ligands and methods of use
WO2025071977A1 (en) * 2023-09-28 2025-04-03 The Johns Hopkins University Pet/ct atlas for segmentation
WO2025088147A1 (en) 2023-10-27 2025-05-01 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis
KR20250062978A (ko) * 2023-10-31 2025-05-08 서울대학교병원 신규한 전립선 특이적 막 항원 리간드 및 이의 용도
WO2025128807A1 (en) 2023-12-13 2025-06-19 Amgen Inc. Radiolabeled compounds for the detection of steap1
WO2025218879A1 (en) 2024-04-15 2025-10-23 Itm Technologies Munich Se Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same

Family Cites Families (344)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
DE3376114D1 (en) 1982-12-07 1988-05-05 Kyowa Hakko Kogyo Kk Mitomycin analogues
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体，その製造法および抗腫瘍剤
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US5103018A (en) 1986-08-26 1992-04-07 Kyowa Hakko Kogyo Kabushiki Kaisha Mitomycin derivatives
USH806H (en) 1987-07-16 1990-08-07 Fmc Corporation Herbicidal clomazone compositions and methods of use tolerant to corn and other crops
WO1991007418A1 (en) 1989-11-13 1991-05-30 Xoma Corporation Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
AU653565B2 (en) 1990-12-21 1994-10-06 Nikken Corporation Raw sewage disposal apparatus and prefab for accomodating the same
US6342491B1 (en) 1991-05-21 2002-01-29 American Home Products Corporation Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
US6291196B1 (en) 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
GB9314623D0 (en) 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
JP3538221B2 (ja) 1993-11-19 2004-06-14 富士写真フイルム株式会社 定着濃厚液およびそれを用いたハロゲン化銀写真感光材料の処理方法
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
JP2000507577A (ja) 1996-04-01 2000-06-20 エピックス メディカル，インコーポレイテッド 画像診断用の生物活性造影剤
WO1997038313A1 (en) 1996-04-05 1997-10-16 The Johns Hopkins University A method of enriching rare cells
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5998362A (en) 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6548260B1 (en) 1997-01-21 2003-04-15 Bayer Corporation Detection of PSA-α2-macroglobulin complex in a biological fluid
US7008765B1 (en) 1997-04-10 2006-03-07 The Johns Hopkins University PCA3, PCA3 genes, and methods of use
WO1998052966A1 (en) 1997-05-19 1998-11-26 The Johns Hopkins University School Of Medecine Tissue specific prodrug
US6504014B1 (en) 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
US6127333A (en) 1997-07-10 2000-10-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20020115596A1 (en) 1997-10-27 2002-08-22 Merk & Co., Inc. Conjugates useful in the treatment of prostate cancer
IL136167A0 (en) 1997-12-02 2001-05-20 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
US20040081659A1 (en) 1997-12-02 2004-04-29 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ZA9810974B (en) 1997-12-02 1999-06-03 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
WO1999045374A2 (en) 1998-03-03 1999-09-10 Mosaic Technologies Purification and detection processes using reversible affinity electrophoresis
US20020103136A1 (en) 1998-03-05 2002-08-01 Dong-Mei Feng Conjugates useful in the treatment of prostate cancer
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
FR2778820B1 (fr) 1998-05-20 2000-07-28 Rhone Poulenc Agrochimie Melanges herbicides a base d'aclonifen et de clomazone
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
DK1086223T3 (da) 1998-06-01 2009-11-30 Agensys Inc Nye serpentintransmembranantigener udtrykt i humane cancerformer og anvendelser deraf
US6518033B1 (en) 1998-08-05 2003-02-11 The Research Foundation Of State University Of New York Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment
US20070020327A1 (en) 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US20030207808A1 (en) 1999-02-18 2003-11-06 Kinneret Savitzky Novel nucleic acid and amino acid sequences
AU4063600A (en) 1999-04-05 2000-10-23 Merck & Co., Inc. A method of treating cancer
US6479470B1 (en) 1999-04-28 2002-11-12 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALAdase
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US20040146516A1 (en) 1999-06-17 2004-07-29 Utah Ventures Ii L.P. Lumen-exposed molecules and methods for targeted delivery
WO2001004309A1 (en) 1999-07-13 2001-01-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services T-CELL RECEPTOR η ALTERNATE READING FRAME PROTEIN, (TARP) AND USES THEREOF
EP1246597B1 (en) 1999-08-03 2015-01-14 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
EP1228089A2 (en) 1999-10-27 2002-08-07 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
NZ521898A (en) 2000-03-31 2004-11-26 Purdue Research Foundation Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
US6933114B2 (en) 2000-10-16 2005-08-23 Gilead Sciences, Inc. Nucleic acid ligands to the prostate specific membrane antigen
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
US7468354B2 (en) 2000-12-01 2008-12-23 Genspera, Inc. Tissue specific prodrugs
JP2004536034A (ja) 2001-01-08 2004-12-02 ネオルクス コーポレイション 治療的および診断的化合物、組成物および方法
MXPA03007037A (es) 2001-02-07 2003-11-18 Beth Israel Hospital Ligandos del antigeno de membrana especifico de prostata (amep) y usos relacionados del mismo.
US7767202B2 (en) 2001-03-16 2010-08-03 The Johns Hopkins University Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules
ES2244793T3 (es) 2001-03-21 2005-12-16 L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO SOCIETA' PER AZIONI Analogos no centrosimetricos de ftalocianina sustituidos por metales, su preparacion y su utilizacion en terapia fotodinamica y diagnostico in vivo.
CA2905585C (en) 2001-03-29 2020-02-18 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for the treatment and/or prevention of cancer or polyps
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
MXPA03010035A (es) 2001-05-02 2004-06-30 Purdue Research Foundation Tratamiento y diagnostico de enfermedades mediadas por macrofagos.
US20040092890A1 (en) 2001-05-10 2004-05-13 Ash Stephen R. Catheter lock solution including a photo-oxidant
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
IL158969A0 (en) 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US20040018203A1 (en) 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
ATE430935T1 (de) 2001-06-21 2009-05-15 Glycomimetics Inc Nachweis und behandlung von prostatakrebs
EP1409017A4 (en) 2001-06-25 2006-05-24 Drug Innovation & Design Inc CELL TARGETING INVOLVING THE RECONNAISSANCE OF EXPONENTIAL FORMS, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS
US7755757B2 (en) 2007-02-14 2010-07-13 Chemimage Corporation Distinguishing between renal oncocytoma and chromophobe renal cell carcinoma using raman molecular imaging
WO2003004469A1 (en) 2001-07-02 2003-01-16 Dabur Research Foundation Anticancer activity of imino acid conjugates of methylglyoxal
US6596755B2 (en) 2001-07-02 2003-07-22 Dabur Research Foundation Oral formulation of methylglyoxal and its imino acid conjugates for human use
US7893223B2 (en) 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
US7282476B2 (en) 2001-08-24 2007-10-16 University Of Victoria Innovation And Development Corporation Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
WO2003024388A2 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
US20030232760A1 (en) 2001-09-21 2003-12-18 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DK1434603T3 (da) 2001-09-28 2010-04-26 Purdue Research Foundation Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater
US20030215456A1 (en) 2001-10-02 2003-11-20 Sui-Long Yao Method of treating cancer
US20030133927A1 (en) 2001-10-10 2003-07-17 Defeo-Jones Deborah Conjugates useful in the treatment of prostate cancer
US20040058857A1 (en) 2001-11-29 2004-03-25 Siu-Long Yao Method of treating cancer
US20070031438A1 (en) 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
AU2002364202A1 (en) 2001-12-21 2003-07-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Novel metastasis suppressor gene on human chromosome 8
CA2473289C (en) 2002-01-10 2014-07-29 The Johns Hopkins University Asymmetric urea compounds useful as naaladase and psma imaging agents
EP1480548A4 (en) 2002-02-06 2006-02-01 Univ Johns Hopkins Med METHODS AND COMPOSITIONS FOR TARGETING SYSTEMIC IMMUNE RESPONSE AGAINST A SPECIFIC ORGAN OR TISSUE
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8491896B2 (en) 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US7282567B2 (en) 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
US20170281791A1 (en) 2002-03-01 2017-10-05 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
EP1497462A4 (en) 2002-03-07 2007-11-07 Univ Johns Hopkins Med GENOMIC SCREEN ON EPIGENETIC MUTED CANCER ASSOCIATED GENES
US7534580B2 (en) 2002-05-01 2009-05-19 Ambrilia Biopharma Inc. PSP94 diagnostic reagents and assays
NZ536467A (en) 2002-05-06 2006-11-30 Endocyte Inc Vitamin-targeted imaging agents
KR20040106547A (ko) 2002-05-15 2004-12-17 엔도사이트, 인코포레이티드 비타민-마이토마이신 공액체
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AR040956A1 (es) 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico
WO2006028429A2 (en) 2002-08-05 2006-03-16 The Johns Hopkins University Peptides for targeting the prostate specific membrane antigen
US7662795B2 (en) 2002-08-08 2010-02-16 The Johns Hopkins University Enhancement of adenoviral oncolytic activity by modification of the E1A gene product
US8487128B2 (en) 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
AU2003303374A1 (en) 2002-12-20 2004-07-22 The Johns Hopkins University Treatment of metastatic cancer with the b-subunit of shiga toxin
US7166691B2 (en) 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
US20080008649A1 (en) * 2003-01-13 2008-01-10 Bracco Imaging S.P.A. Gastrin Releasing Peptide Compounds
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
CA2512867C (en) 2003-01-27 2014-08-26 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
EP1587837B1 (en) 2003-01-28 2012-06-13 Proscan RX Pharma Inc. Epitope sequences for prostate cancer diagnosis and treatment
EP1444990A1 (en) 2003-02-07 2004-08-11 Amersham plc Improved Radiometal Complex Compositions
US7189723B2 (en) 2003-02-10 2007-03-13 Cgi Pharmaceuticals, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
WO2004080412A2 (en) 2003-03-07 2004-09-23 The University Of Toledo Paclitaxel hybrid derivatives
US20070179100A1 (en) 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
EP2660322A3 (en) 2003-04-17 2013-11-13 Alnylam Pharmaceuticals Inc. Modified iRNA agents
US7605182B2 (en) 2003-05-01 2009-10-20 Aposense Ltd. Compounds that selectively bind to membranes of apoptotic cells
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7172751B2 (en) 2003-06-13 2007-02-06 Immunomedics, Inc. D-amino acid peptides
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
WO2005051315A2 (en) 2003-11-24 2005-06-09 The Regents Of The University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
FR2864546A1 (fr) 2003-12-24 2005-07-01 Assist Publ Hopitaux De Paris Methode d'identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations
BRPI0506771A (pt) 2004-01-12 2007-05-22 Applied Molecular Evolution anticorpo, e, composição farmacêutica
US8586932B2 (en) 2004-11-09 2013-11-19 Spectrum Dynamics Llc System and method for radioactive emission measurement
WO2006051531A2 (en) 2004-11-09 2006-05-18 Spectrum Dynamics Llc Radioimaging
DE102004004787A1 (de) 2004-01-30 2005-08-18 Schering Ag Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005094882A1 (en) 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US20070254317A1 (en) 2004-03-03 2007-11-01 Biomerieux Method for Detecting the Activatable Free Form of Psa and the Use Thereof for Diagnosing Benign Pathologies of the Prostate and Adenocarcinoma of the Prostate
ES2311895T3 (es) 2004-03-15 2009-02-16 F. Hoffmann-La Roche Ag El uso de los peptidos tipo bnp y de los peptidos tipo anf para evaluar el riesgo de padecer una complicacion cardio-vascular como frecuencia de sobrecarga del volumen.
CA2606138A1 (en) 2004-04-19 2005-10-27 Proscan Rx Pharma Prostate cancer diagnosis and treatment
WO2005111238A2 (en) 2004-04-19 2005-11-24 Archemix Corporation Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
CA2564076C (en) 2004-05-19 2014-02-18 Medarex, Inc. Chemical linkers and conjugates thereof
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US20060148741A1 (en) 2004-07-26 2006-07-06 Government Of The Usa, Represented By The Secretary, Department Of Health And Human Services Metastasis suppressor gene on human chromosome 8 and its use in the diagnosis, prognosis and treatment of cancer
JP5055603B2 (ja) 2004-08-04 2012-10-24 メントリック・バイオテック・リミテッド・ライアビリティ・カンパニー 変異Ｆｃ領域
US20060045883A1 (en) 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
JP2008511552A (ja) 2004-08-30 2008-04-17 ニューロメッド ファーマシューティカルズ リミテッド カルシウムチャネルブロッカーとしての尿素誘導体
US8194660B2 (en) 2004-09-09 2012-06-05 Amx Llc System, method, and computer-readable medium for dynamic device discovery for servers binding to multiple masters
US7713944B2 (en) 2004-10-13 2010-05-11 Isis Pharmaceuticals, Inc. Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells
CN101087783B (zh) 2004-10-27 2010-12-08 詹森药业有限公司 作为黄体酮受体调节剂的三取代噻吩类化合物
US8423125B2 (en) 2004-11-09 2013-04-16 Spectrum Dynamics Llc Radioimaging
US20060140871A1 (en) 2004-11-30 2006-06-29 Sillerud Laurel O Magnetic resonance imaging of prostate cancer
US7872235B2 (en) 2005-01-13 2011-01-18 Spectrum Dynamics Llc Multi-dimensional image reconstruction and analysis for expert-system diagnosis
US7741510B2 (en) 2005-01-13 2010-06-22 E. I. Du Pont De Nemours And Company Rheology control agents
US20060155021A1 (en) 2005-01-13 2006-07-13 Lenges Christian P Coating compositions containing rheology control agents
CA2596469A1 (en) 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of H Ealth & Human Services Biomarkers for tissue status
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
US20090105172A1 (en) 2005-03-07 2009-04-23 Diener John L Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
KR101068612B1 (ko) 2005-05-24 2011-09-30 휴마시스 주식회사 유사구조 단백질 비율 측정을 이용한 진단장치
NZ564954A (en) 2005-06-14 2011-02-25 Protox Therapeutics Inc Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
CN103127523A (zh) 2005-06-20 2013-06-05 Psma开发有限公司 Psma抗体-药物缀合物
WO2007006041A2 (en) 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
US20070010014A1 (en) 2005-07-06 2007-01-11 General Electric Company Compositions and methods for enhanced delivery to target sites
EP1909853B1 (en) 2005-07-19 2015-03-18 Biosensors International Group, Ltd. Imaging protocols
EP2382995A3 (en) 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
JP2009504786A (ja) 2005-08-19 2009-02-05 シーラス コーポレイション リステリア属誘導型免疫漸増および活性化、ならびにその使用方法
BRPI0615354A2 (pt) 2005-08-19 2011-05-17 Endocyte Inc conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
EP2015781A4 (en) 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
JP5368099B2 (ja) 2005-10-07 2013-12-18 ゲルベ ガリウムと錯体形成することが可能なシグナル部分にカップリングされた、生物学的標的の認識のための部分を含んでなる化合物
JP2009518289A (ja) 2005-11-21 2009-05-07 メディバス エルエルシー 高分子の送達用ポリマー粒子および使用方法
AU2006318438B2 (en) 2005-11-23 2011-09-22 Ventana Medical Systems, Inc. Molecular conjugate
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
WO2007087131A2 (en) 2006-01-05 2007-08-02 The Johns Hopkins University Peptide prodrugs
US7635682B2 (en) 2006-01-06 2009-12-22 Genspera, Inc. Tumor activated prodrugs
US20070212337A1 (en) 2006-02-01 2007-09-13 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
CN101443340B (zh) 2006-03-14 2013-12-04 癌靶技术有限责任公司 前列腺特异性膜抗原的拟肽抑制剂、含该拟肽抑制剂的化合物及用法
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
US20140314864A1 (en) 2006-03-31 2014-10-23 Massachusetts Institute Of Technology System for Targeted Delivery of Therapeutic Agents
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
US7842280B2 (en) 2006-09-06 2010-11-30 Case Western Reserve University Flexibly labeling peptides
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
ES2547481T3 (es) 2006-11-08 2015-10-06 Molecular Insight Pharmaceuticals, Inc. Heterodímeros de ácido glutámico
US9387344B2 (en) 2006-11-21 2016-07-12 The Johns Hopkins University Methods for determining absorbed dose information
AU2007328207A1 (en) 2006-12-05 2008-06-12 Landec Corporation Drug delivery
WO2008085828A2 (en) 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
CA2675202C (en) 2007-01-11 2014-09-16 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
AU2007345648A1 (en) 2007-01-26 2008-08-07 City Of Hope Methods and compositions for the treatment of cancer or other diseases
AU2008213702B2 (en) 2007-02-07 2014-04-24 Purdue Research Foundation Positron emission tomography imaging method
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
WO2008124197A1 (en) 2007-04-10 2008-10-16 The Johns Hopkins University Imaging and therapy of virus-associated tumors
CA2690943A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
AU2008269094B2 (en) * 2007-06-26 2015-04-09 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
GB0723246D0 (en) 2007-07-03 2008-01-09 Barton Michelle p53 modulator
CA2693707A1 (en) 2007-07-13 2009-03-05 The Johns Hopkins University B7-dc variants
JP2010535248A (ja) 2007-07-31 2010-11-18 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍性障害または感染症の免疫学的予防または免疫療法のためのポリペプチド−核酸複合体
WO2009021178A1 (en) 2007-08-08 2009-02-12 Chemimage Corporation Raman difference spectra based disease classification
EP3838298B1 (en) 2007-08-17 2025-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
WO2009033161A1 (en) 2007-09-07 2009-03-12 The John Hopkins University Adenosine receptor agonists and antagonists to modulate t cell responses
HUE035101T2 (hu) 2007-09-28 2018-05-02 Pfizer Ráksejtek célzása nanorészecskék alkalmazásával
JP2011500835A (ja) 2007-10-25 2011-01-06 エンドサイト，インコーポレイテッド チューブリシン類および調製プロセス
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
EP2231194B1 (en) 2007-12-04 2017-02-22 Alnylam Pharmaceuticals Inc. Folate-irna conjugates
WO2009076434A1 (en) 2007-12-12 2009-06-18 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
CN102083427B (zh) 2008-01-09 2014-12-10 分子洞察制药公司 碳酸酐酶ix的抑制剂
US8565945B2 (en) 2008-01-17 2013-10-22 Lockheed Martin Corporation Method for managing vital train movements
CA2720571A1 (en) 2008-04-04 2009-10-08 Molecular Insight Pharmaceuticals, Inc. Radiolabeled treatment infusion system, apparatus, and methods of using the same
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
EP2285960B1 (en) 2008-05-08 2015-07-08 Asuragen, INC. Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis
CA2723816C (en) 2008-05-13 2017-06-20 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
ES2765240T3 (es) 2008-06-16 2020-06-08 Pfizer Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
WO2010002418A2 (en) 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
HRP20171133T1 (hr) 2008-08-01 2017-10-20 The Johns Hopkins University Psma-vezujući agensi i njihove uporabe
US8685937B2 (en) 2008-08-09 2014-04-01 University Of Iowa Research Foundation Nucleic acid aptamers
WO2010027641A2 (en) 2008-08-15 2010-03-11 Georgetown University Na channels, disease, and related assays and compositions
EP2727606A3 (en) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2349274B1 (en) 2008-09-17 2025-04-09 Endocyte, Inc. Folate receptor binding conjugates of antifolates
US20110288152A1 (en) 2008-10-17 2011-11-24 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
CN102272100B (zh) 2008-12-05 2016-08-17 分子制药洞察公司 用于抑制psma的锝-和铼-双(杂芳基)络合物及其使用方法
LT3903829T (lt) 2009-02-13 2023-06-12 Immunomedics, Inc. Imunokonjugatai su viduląsteliniu būdu skaldoma jungtimi
US10517969B2 (en) 2009-02-17 2019-12-31 Cornell University Methods and kits for diagnosis of cancer and prediction of therapeutic value
US20100260677A1 (en) 2009-03-02 2010-10-14 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
US8772226B2 (en) 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer
US10717750B2 (en) 2009-03-19 2020-07-21 The Johns Hopkins University 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents
EP3222617B1 (en) * 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
US9757084B2 (en) 2011-12-22 2017-09-12 The Johns Hopkins University Method and system for administering radiopharmaceutical therapy (RPT)
CN102714296A (zh) 2009-05-19 2012-10-03 Aic布莱博公司 复合集电器及形成其的方法
BR112012000210A2 (pt) 2009-06-15 2019-09-24 Molecular Insight Pharm Inc processo para a produção de heterodímeoros de ácido glutâmico.
CN104857534A (zh) 2009-07-31 2015-08-26 恩多塞特公司 叶酸盐靶向的诊断和治疗
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011031517A1 (en) 2009-08-27 2011-03-17 Nuclea Biotechnologies, LLC Method and assay for determining fas expression
JP6251477B2 (ja) 2009-12-02 2017-12-20 イマジナブ・インコーポレーテッド ヒト前立腺特異的膜抗原（ｐｓｍａ）をターゲッティングするｊ５９１ミニボディおよびｃｙｓダイアボディならびにこれらを使用するための方法
JP5891175B2 (ja) 2009-12-11 2016-03-22 バインド セラピューティックス インコーポレイテッド 治療用粒子の凍結乾燥に対する安定製剤
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
US20120322741A1 (en) 2010-02-25 2012-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2011109422A2 (en) 2010-03-02 2011-09-09 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of cancer
JP2010159277A (ja) 2010-03-04 2010-07-22 Sumitomo Chemical Co Ltd 有害生物防除組成物及び有害生物の防除方法
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US9006415B2 (en) 2010-04-06 2015-04-14 Massachusetts Institute Of Technology Targeted delivery of nucleic acids
MA34277B1 (fr) 2010-04-15 2013-06-01 Spirogen Developments Sarl Pyrrolobenzodiazépines et conjugués de celles-ci
US8858509B2 (en) 2010-05-05 2014-10-14 Safety Syringes, Inc. Needle based helical coil safety device
CN101863924B (zh) 2010-05-17 2012-06-27 北京师范大学 99mTc标记肼基烟酰胺基-二氧辛酰-叶酸配合物及制备方法
AU2011279024A1 (en) 2010-07-16 2013-02-21 The Johns Hopkins University Methods and compositions for cancer immunotherapy
US9029340B2 (en) 2010-07-22 2015-05-12 The Johns Hopkins University Radiation sensitization agents for prostate cancer
WO2012033911A2 (en) 2010-09-08 2012-03-15 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines
KR101236142B1 (ko) 2010-09-30 2013-02-21 경북대학교 산학협력단 가돌리늄 착물을 함유하는 ｍｒｉ조영제
ES2675320T3 (es) 2010-12-06 2018-07-10 Molecular Insight Pharmaceuticals, Inc. Dendrímeros dirigidos a PSMA
CN103561773A (zh) 2011-03-31 2014-02-05 约翰霍普金斯大学 治疗诊断显像剂和使用方法
EP2694553B1 (en) 2011-04-01 2017-10-11 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
CA2831338C (en) 2011-04-21 2018-07-17 Orion Corporation Androgen receptor modulating carboxamides
US9180214B1 (en) 2011-04-22 2015-11-10 Stc.Unm Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer
US9717484B2 (en) 2011-05-06 2017-08-01 The Johns Hopkins University Method and device for statistical tissue sampling using microdevices
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
EP2721039B1 (en) * 2011-06-15 2018-01-10 Cancer Targeted Technology LLC Chelated psma inhibitors
AU2012294639B2 (en) * 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
WO2013060793A1 (en) * 2011-10-25 2013-05-02 Technische Universität München Bifunctional ligands for radiometals
WO2013070457A2 (en) 2011-11-01 2013-05-16 The Johns Hopkins University Method and device for endoscopic abrasion
EP3524277B1 (en) 2011-11-30 2023-03-08 The Johns Hopkins University Psma-targeting compound and uses thereof
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
EP2822386B1 (en) 2012-02-29 2021-05-05 Purdue Research Foundation Folate receptor alpha binding ligands
WO2013138612A1 (en) 2012-03-14 2013-09-19 The Johns Hopkins University Synthesis and application of novel imaging agents conjugated to dpa 713 analogs for imaging inflammation
WO2013166110A1 (en) 2012-05-02 2013-11-07 Yale University Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
CN104507538B (zh) 2012-06-08 2018-04-06 艾杜罗生物科技公司 癌症免疫疗法的组合物和方法
NZ704487A (en) 2012-07-27 2018-05-25 Aragon Pharmaceuticals Inc Methods and compositions for determining resistance to androgen receptor therapy
US20140107316A1 (en) 2012-10-16 2014-04-17 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
CA2887727A1 (en) 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
US20140113322A1 (en) 2012-10-22 2014-04-24 The Johns Hopkins University Supramolecular nanobeacon imaging agents as protease sensors
US9180203B2 (en) 2012-10-23 2015-11-10 The Johns Hopkins University Self-assembling drug amphiphiles and methods for synthesis and use
HK1211493A1 (en) 2012-11-15 2016-05-27 恩多塞特公司 Conjugates for treating diseases caused by psma expressing cells
US20140154702A1 (en) 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
KR102002826B1 (ko) 2012-12-04 2019-07-23 삼성전자 주식회사 저장 장치, 플래시 메모리 및 저장 장치의 동작 방법
HK1216176A1 (zh) 2012-12-21 2016-10-21 Medlmmune Limited 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
CN110179995A (zh) 2012-12-28 2019-08-30 塔弗达治疗有限公司 包封在颗粒中的靶向缀合物及其制剂
CN105025933B (zh) 2013-01-14 2019-03-26 分子制药洞察公司 三嗪类放射性药物和放射性显影剂
US9889199B2 (en) 2013-02-15 2018-02-13 Case Western Reserve University PSMA ligands and uses thereof
US10207005B2 (en) 2013-02-15 2019-02-19 Case Western Reserve University Photodynamic therapy composition
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
US9255262B2 (en) 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
US9567402B2 (en) 2013-03-14 2017-02-14 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate and other cancer cells
US10434194B2 (en) 2013-06-20 2019-10-08 Case Western Reserve University PSMA targeted nanobubbles for diagnostic and therapeutic applications
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
JP5817799B2 (ja) 2013-10-10 2015-11-18 ダイキン工業株式会社 空気調和機
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015057692A1 (en) 2013-10-14 2015-04-23 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
WO2015058151A2 (en) 2013-10-18 2015-04-23 Molecular Insight Pharmaceuticals, Inc. Methods of using spect/ct analysis for staging cancer
WO2015057250A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
EP3415489A1 (en) * 2013-10-18 2018-12-19 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
SG10201803618RA (en) 2013-11-14 2018-06-28 Endocyte Inc Compounds for positron emission tomography
ITAN20130219A1 (it) 2013-11-21 2015-05-22 Gianluca Valentini Farmaco anti-cancro, comprendente un radioisotopo del rame
EA201690806A1 (ru) 2013-11-25 2016-09-30 Оксфорд Байотерапьютикс Лтд. Антитела
US9346846B1 (en) 2013-12-02 2016-05-24 Yale University Anti-cancer compounds and methods for treating cancer
CN105828863B (zh) 2013-12-18 2020-06-09 皇家飞利浦有限公司 基于心脏或呼吸特性来增强睡眠慢波活动的系统和方法
WO2015143029A1 (en) 2014-03-18 2015-09-24 The Johns Hopkins University Psma-based molecular-genetic reporter system
CA2950892C (en) 2014-05-06 2023-10-24 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
EP2944635B1 (en) 2014-05-15 2018-11-28 Council of Scientific & Industrial Research Pyrazole linked benzimidazole conjugates and a process for preparation thereof
US9814759B2 (en) 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
CA2961575C (en) 2014-08-06 2023-09-19 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (psma) inhibitors
HUE058072T2 (hu) 2014-08-06 2022-07-28 Univ Johns Hopkins Prosztata-fajlagos membrán antigén (PSMA) inhibitor elõgyógyszerei
PL3183236T3 (pl) 2014-08-24 2022-07-18 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma
EP2993171A1 (en) 2014-09-04 2016-03-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18F-labeled PSMA-specific PET-tracers
EP3186393A4 (en) 2014-08-25 2018-01-10 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
US9956305B2 (en) 2014-09-08 2018-05-01 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
WO2016062370A1 (en) 2014-10-20 2016-04-28 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2016065142A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
WO2016081835A2 (en) 2014-11-21 2016-05-26 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
US20180148480A1 (en) 2015-01-16 2018-05-31 The Johns Hopkins University Synthetic enhancement of the t-cell armamentarium as an anti-cancer therapy
WO2016115415A1 (en) 2015-01-16 2016-07-21 The Johns Hopkins University Albumin-proaerolysin prodrugs
EP3283100A2 (en) 2015-04-13 2018-02-21 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
JP7114457B2 (ja) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
US9808538B2 (en) 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
KR101639599B1 (ko) 2015-11-09 2016-07-14 서울대학교산학협력단 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물
FR3043970B1 (fr) 2015-11-25 2019-06-21 Medtech Sa Systeme mecanique de stabilisation au sol pour vehicules a roulettes
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
US10308606B2 (en) 2016-09-09 2019-06-04 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
SG11201909513QA (en) 2017-04-11 2019-11-28 Univ Johns Hopkins Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
IL275317B (en) 2017-12-13 2022-09-01 Sciencons AS A complex containing a compound against psma attached to a radioactive nucleus of lead or thorium
CN118852331A (zh) 2018-02-22 2024-10-29 美国政府健康及人类服务部 伊文思蓝衍生物的化学缀合物及其作为靶向前列腺癌的放射疗法和显像剂的用途
SG11202012729YA (en) 2018-06-21 2021-01-28 Regeneron Pharma Bispecific anti-psma x anti-cd28 antibodies and uses thereof

Also Published As

Publication number Publication date
JP7194161B2 (ja) 2022-12-21
MX2016005013A (es) 2017-02-28
CY2024023I1 (el) 2025-05-09
LT4095130T (lt) 2024-04-25
HUS2400024I1 (hu) 2024-08-28
JP2021059557A (ja) 2021-04-15
US11045564B2 (en) 2021-06-29
AU2020201086A1 (en) 2020-03-05
FI4095130T3 (fi) 2024-04-25
HRP20240398T1 (hr) 2024-06-07
EP3038996A1 (en) 2016-07-06
GEP20237479B (en) 2023-03-27
AU2018200419B2 (en) 2019-11-14
GEP20237497B (en) 2023-04-10
AU2018200419A1 (en) 2018-02-08
EP4095130A1 (en) 2022-11-30
DE202014011593U1 (de) 2023-08-23
MY194484A (en) 2022-11-30
CA2924360A1 (en) 2015-04-23
TN2016000137A1 (en) 2017-10-06
US20190336622A1 (en) 2019-11-07
NL301281I2 (nl) 2024-08-01
PE20211760A1 (es) 2021-09-07
PH12019502571A1 (en) 2023-04-03
DK4095130T3 (da) 2024-04-22
US20210177996A1 (en) 2021-06-17
HUE066137T2 (hu) 2024-07-28
JP2024028742A (ja) 2024-03-05
CY2024023I2 (el) 2025-05-09
US20190060491A1 (en) 2019-02-28
CN105636924A (zh) 2016-06-01
CN109053616B (zh) 2022-08-19
FR24C1028I1 (fr) 2024-08-30
KR20210013350A (ko) 2021-02-03
KR102282378B1 (ko) 2021-07-27
FIC20240024I1 (fi) 2024-06-28
GEP20217330B (en) 2021-12-10
EP4095130B1 (en) 2024-01-31
JP2019011368A (ja) 2019-01-24
KR101947053B1 (ko) 2019-02-12
ES2977715T3 (es) 2024-08-29
RS65324B1 (sr) 2024-04-30
GEAP202114132A (en) 2021-06-10
JP2016535013A (ja) 2016-11-10
NZ718812A (en) 2017-08-25
EP4374924A2 (en) 2024-05-29
JP2018058847A (ja) 2018-04-12
KR20190016133A (ko) 2019-02-15
ZA201907607B (en) 2021-05-26
PH12016500656A1 (en) 2016-06-13
SG11201602249RA (en) 2016-05-30
CN109053616A (zh) 2018-12-21
GEP20237496B (en) 2023-04-10
MY188934A (en) 2022-01-13
IL268974B (en) 2020-08-31
US20240350680A1 (en) 2024-10-24
FR24C1028I2 (fr) 2025-03-28
SI4095130T1 (sl) 2024-05-31
JP2022159345A (ja) 2022-10-17
SA516370842B1 (ar) 2020-06-07
MX2021008977A (es) 2021-09-08
MX2021008976A (es) 2021-08-18
AU2014336638C1 (en) 2020-09-17
WO2015055318A1 (en) 2015-04-23
LTPA2024522I1 (enExample) 2024-07-25
DE202014011600U1 (de) 2023-05-31
JP6556805B2 (ja) 2019-08-07
IL245113A0 (en) 2016-06-30
US20240382631A1 (en) 2024-11-21
EP3415489A1 (en) 2018-12-19
KR102210931B1 (ko) 2021-02-02
EP3456700A1 (en) 2019-03-20
PH12016500656B1 (en) 2016-06-13
US20260007785A1 (en) 2026-01-08
AU2014336638A1 (en) 2016-04-14
US20190374660A1 (en) 2019-12-12
US11931430B2 (en) 2024-03-19
EP3495355A1 (en) 2019-06-12
EP4374924A3 (en) 2024-08-07
AU2014336638B2 (en) 2017-10-19
CA2924360C (en) 2022-04-26
US20190008988A1 (en) 2019-01-10
PE20160678A1 (es) 2016-08-06
US20210283279A1 (en) 2021-09-16
US10398791B2 (en) 2019-09-03
IL245113B (en) 2020-08-31
PL4095130T3 (pl) 2024-06-10
JP7393485B2 (ja) 2023-12-06
US20260007784A1 (en) 2026-01-08
AU2020201086B2 (en) 2021-07-08
JP6901451B2 (ja) 2021-07-14
ZA201603380B (en) 2020-05-27
US11951190B2 (en) 2024-04-09
US20160228587A1 (en) 2016-08-11
GEAP202215377A (en) 2022-11-10
US10471160B2 (en) 2019-11-12
EP3038996B1 (en) 2022-06-15
HK1221711A1 (zh) 2017-06-09
IL268974A (en) 2019-10-31
GEAP202215720A (en) 2022-12-26
JP2019218351A (ja) 2019-12-26
EA037778B1 (ru) 2021-05-20
EA201690495A1 (ru) 2016-10-31
KR20160063398A (ko) 2016-06-03
CN105636924B (zh) 2018-08-07
JP7036774B2 (ja) 2022-03-15
GEAP202215719A (en) 2022-12-26

Similar Documents

Publication Publication Date Title
CL2016000883A1 (es) Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma.
LT2847225T (lt) Antikūnai prieš klaudiną 18.2 tinkami vėžio diagnozavimui
EA201791167A1 (ru) Способы и композиции для мечения радиоактивным изотопомf биологических препаратов
MX370597B (es) Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.
MA34091B1 (fr) Anticorps anti-cd40
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2015002628A1 (es) Compuestos de heteroarilo y sus usos.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
GEAP202014748A (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
LT2970345T (lt) 18f-žymėti pozitronų emisijos tomografijos (pet) vizualizacijos agentai, nukreipti į prostatos atžvilgiu specifinius membranos antigenus (psma)
EP3006465A4 (en) Anti-vegf antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
EA201690263A1 (ru) Улучшенные способы получения перампанеля
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
PA8747801A1 (es) Marcaciòn radioactiva por fluoraciòn de aziridinas
WO2015013233A3 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
PL3431490T3 (pl) Związki chemiczne mające zastosowanie jako markery diagnostyczne stanu zapalnego i nowotworów, sposób ich otrzymywania, zestaw diagnostyczny i metoda diagnozowania procesów zapalnych i nowotworów nabłonkowych
CL2013001531A1 (es) Extracto de senecio graveolens, procedimiento de obtencion y uso de composiciones farmaceuticas del extracto y su compuesto mayoritario para el tratamiento de patologias cancerosas y bacterianas.